跳至主要内容
临床试验/NCT00089050
NCT00089050已完成2 期

A Phase II Trial Combining Gemtuzumab Ozogamicin (Mylotarg) With Cyclosporine for the Treatment of Relapsed Acute Myeloid Leukemia in Adults Over Age 60

Fred Hutchinson Cancer Center2 个研究点 分布在 1 个国家开始时间: 2004年5月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
试验地点
2
主要终点
Efficacy in terms of complete remission rate

研究概览

简要总结

RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Cyclosporine may increase the effectiveness of gemtuzumab ozogamicin by making cancer cells more sensitive to the drug. Combining gemtuzumab ozogamicin with cyclosporine may kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving gemtuzumab ozogamicin together with cyclosporine works in treating older patients with relapsed acute myeloid leukemia.

详细描述

OBJECTIVES:

Primary

  • Determine the efficacy of gemtuzumab ozogamicin and cyclosporine, in terms of the complete remission rate, in older patients with relapsed acute myeloid leukemia.
  • Determine the toxicity and pharmacokinetics of this regimen in these patients.

Secondary

  • Correlate clinical response with laboratory studies of drug susceptibility in patients treated with this regimen.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
60 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Efficacy in terms of complete remission rate

Toxicity

Pharmacokinetics

次要结局

  • Correlate clinical response to laboratory studies of drug susceptibility

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验